Skip to Content


In the US, Votrient (pazopanib systemic) is a member of the drug class VEGF/VEGFR inhibitors and is used to treat Renal Cell Carcinoma and Soft Tissue Sarcoma.

US matches:

UK matches:

Ingredient matches for Votrient


Pazopanib is reported as an ingredient of Votrient in the following countries:

  • Bosnia & Herzegowina
  • Indonesia
  • Italy
  • Lithuania
  • Portugal
  • Serbia
  • Slovakia
  • Slovenia
  • Turkey

Pazopanib hydrochloride (a derivative of Pazopanib) is reported as an ingredient of Votrient in the following countries:

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Canada
  • Chile
  • Colombia
  • Costa Rica
  • Croatia (Hrvatska)
  • Czech Republic
  • Denmark
  • El Salvador
  • Finland
  • France
  • Germany
  • Greece
  • Guatemala
  • Honduras
  • Hong Kong
  • Hungary
  • Iceland
  • Ireland
  • Israel
  • Japan
  • Latvia
  • Malaysia
  • Mexico
  • Netherlands
  • New Zealand
  • Norway
  • Philippines
  • Poland
  • Romania
  • Singapore
  • Spain
  • Sweden
  • Switzerland
  • Thailand
  • United Kingdom
  • United States
  • Vietnam

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.